Obeticholic Acid: First Global Approval

  • Drugs. 2016 Aug;76(12):1221-6. doi: 10.1007/s40265-016-0616-x.
A Markham  1 ,  Susan J Keam  2
Affiliations
  • 1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand.
  • 2. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. [email protected].
PMID: 27406083 DOI: 10.1007/s40265-016-0616-x
Abstract

Obeticholic acid (Ocaliva(TM)) is a farnesoid-X receptor (FXR) agonist that is being developed by Intercept Pharmaceuticals for the treatment of various liver diseases, and has recently been granted accelerated approval in the USA for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid, or as monotherapy in adults unable to tolerate ursodeoxycholic acid. The drug is in preregistration for this indication in the EU. This article summarizes the milestones in the development of obeticholic acid leading to this first approval for primary biliary cholangitis.

Products